Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia
source: PLOS ONE
year: 2016
authors: Schaefer BA, Flanagan JM, Alvarez OA, Nelson SC, Aygun B, Nottage KA, George A, Roberts CW, Piccone CM, Howard TA, Davis BR, Ware RE
summary/abstract:Discovery and validation of genetic variants that influence disease severity in children with sickle cell anemia (SCA) could lead to early identification of high-risk patients, better screening strategies, and intervention with targeted and preventive therapy. We hypothesized that newly identified genetic risk factors for the general African American population could also impact laboratory biomarkers known to contribute to the clinical disease expression of SCA, including variants influencing the white blood cell count and the development of albuminuria and abnormal glomerular filtration rate. We first investigated candidate genetic polymorphisms in well-characterized SCA pediatric cohorts from three prospective NHLBI-supported clinical trials: HUSTLE, SWiTCH, and TWiTCH. We also performed whole exome sequencing to identify novel genetic variants, using both a discovery and a validation cohort. Among candidate genes, DARC rs2814778 polymorphism regulating Duffy antigen expression had a clear influence with significantly increased WBC and neutrophil counts, but did not affect the maximum tolerated dose of hydroxyurea therapy. The APOL1 G1 polymorphism, an identified risk factor for non-diabetic renal disease, was associated with albuminuria. Whole exome sequencing discovered several novel variants that maintained significance in the validation cohorts, including ZFHX4 polymorphisms affecting both the leukocyte and neutrophil counts, as well as AGGF1, CYP4B1, CUBN, TOR2A, PKD1L2, and CD163 variants affecting the glomerular filtration rate. The identification of robust, reliable, and reproducible genetic markers for disease severity in SCA remains elusive, but new genetic variants provide avenues for further validation and investigation.
organization: Cincinnati Children's Hospital Medical Center; Baylor College of Medicine,USA; University of Miami; Children's Hospitals and Clinics of Minnesota,USA; Cohen Children's Medical Center, USA; St. Jude Children's Research Hospital, Memphis; University of South Carolina; Case Western Reserve University, Cleveland, OH; University of Texas School of Public HealthDOI: 10.1371/journal.pone.0164364
read more full text
Related Content
-
Sickle cell diseaseSickle cell disease is the name for a gr...
-
Sickle cell trait and diabetes tests: What every healthcare provider should knowAccording to the National Institute of D...
-
Study challenges view that sickle cell trait increases mortality riskSurprising findings from a study of heal...
-
FDA Approves Novel Treatment to Target Abnormality in Sickle Cell DiseaseToday, the U.S. Food and Drug Administra...
-
Identifying Outcomes for Sickle Cell Disease Clinical Trials is Aim of coreSCDThe Green Park Collaborative (GPC) is wo...
-
Sickle Cell Disease and Its Toll Compared in Different Age Groups in StudyDifferences in comorbidities, pain, heal...
-
California’s Stem Cell Agency Invests in Stem Cell-Based Therapies Targeting Sickle Cell Disease and CancerThe California Institute for Regenerativ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.